Compare AA & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AA | NBIX |
|---|---|---|
| Founded | 1888 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aluminum | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.9B | 13.2B |
| IPO Year | 2016 | 1996 |
| Metric | AA | NBIX |
|---|---|---|
| Price | $60.07 | $132.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 21 |
| Target Price | $43.85 | ★ $177.05 |
| AVG Volume (30 Days) | ★ 7.8M | 1.1M |
| Earning Date | 01-22-2026 | 02-05-2026 |
| Dividend Yield | ★ 0.67% | N/A |
| EPS Growth | N/A | ★ 12.44 |
| EPS | ★ 4.31 | 4.19 |
| Revenue | ★ $12,868,000,000.00 | $2,682,700,000.00 |
| Revenue This Year | $9.94 | $23.59 |
| Revenue Next Year | $6.97 | $18.65 |
| P/E Ratio | ★ $13.94 | $31.58 |
| Revenue Growth | 16.94 | ★ 19.61 |
| 52 Week Low | $21.53 | $84.23 |
| 52 Week High | $66.95 | $160.18 |
| Indicator | AA | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 60.44 | 35.61 |
| Support Level | $58.47 | $131.30 |
| Resistance Level | $66.95 | $135.98 |
| Average True Range (ATR) | 2.46 | 3.27 |
| MACD | -0.17 | -0.68 |
| Stochastic Oscillator | 54.09 | 8.58 |
Alcoa is a vertically integrated aluminum company whose operations include bauxite mining, alumina refining, and manufacturing primary aluminum. It is the world's largest bauxite miner and alumina refiner by production volume, and the eighth-largest aluminum producer. Profits are closely tied to prevailing commodity prices along the aluminum supply chain.Alcoa was the first mass producer of aluminum, launching the world-changing Hall-Heroult smelting process in the 1880s, making aluminum affordable. It listed as a public company in 1925. In 2016, Alcoa spun off its automotive and aerospace metal parts segment to focus on mining, smelting, and refining. It bought the 40% unowned balance of AWAC in mid-2024, meaning refining assets are now predominantly wholly owned, as with smelting.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.